{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:16:40Z","timestamp":1789647400657,"version":"4.0.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcv.2026.105971","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:06:27Z","timestamp":1782803187000},"page":"105971","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5"],"prefix":"10.1016","volume":"185","author":[{"given":"Julia Carolin","family":"Eichholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Sandmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jcv.2026.105971_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","article-title":"The global prevalence of hepatitis D virus infection: systematic review and meta-analysis","volume":"73","author":"Stockdale","year":"2020","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.jcv.2026.105971_bib2","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1093\/infdis\/jiz633","article-title":"Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection","volume":"221","author":"Miao","year":"2020","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.jcv.2026.105971_bib3","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1002\/hep.31214","article-title":"Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on Liver-Related outcomes","volume":"72","author":"Kamal","year":"2020","journal-title":"Hepatology"},{"issue":"s1","key":"10.1016\/j.jcv.2026.105971_bib4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1478-3231.2010.02408.x","article-title":"Hepatitis D revival","volume":"31","author":"Wedemeyer","year":"2011","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.jcv.2026.105971_bib5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jhep.2023.05.001","article-title":"EASL clinical practice guidelines on hepatitis delta virus","volume":"79","author":"European Association for the Study of the Liver","year":"2023","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.jcv.2026.105971_bib6","doi-asserted-by":"crossref","first-page":"e715","DOI":"10.1055\/a-2181-3345","article-title":"Antiviral therapy of chronic hepatitis D virus infection \u2013 addendum to the S3 guideline \u201cprophylaxis, diagnosis and therapy of hepatitis B virus infection\u201d of the german society for gastroenterology, digestive and metabolic diseases (DGVS) 1","volume":"61","author":"Sandmann","year":"2023","journal-title":"Z. Gastroenterol."},{"key":"10.1016\/j.jcv.2026.105971_bib7","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2147\/DDDT.S379964","article-title":"Bulevirtide in the treatment of hepatitis delta: Drug discovery, clinical development and place in therapy","volume":"17","author":"Soriano","year":"2023","journal-title":"Drug. Des. Devel Ther."},{"issue":"4","key":"10.1016\/j.jcv.2026.105971_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/jvh.13804","article-title":"Kinetics and predictive value of HBcrAg, HBV RNA and anti-HBc during bulevirtide treatment of chronic HDV-infected, patients","volume":"30","author":"Sandmann","year":"2023","journal-title":"J. Viral Hepat."},{"issue":"2","key":"10.1016\/j.jcv.2026.105971_bib9","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70003","article-title":"Value and kinetics of virological markers in the natural course of chronic hepatitis D virus infection","volume":"45","author":"Sandmann","year":"2025","journal-title":"Liver Int."},{"issue":"1","key":"10.1016\/j.jcv.2026.105971_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2213429","article-title":"A phase 3, randomized trial of bulevirtide in chronic hepatitis D","volume":"389","author":"Wedemeyer","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.jcv.2026.105971_bib11","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV\/HDV treatment endpoints conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jcv.2026.105971_bib12","article-title":"HDV RNA assays: performance characteristics, clinical utility, and challenges","author":"Wedemeyer","year":"2023","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jcv.2026.105971_bib13","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1097\/HEP.0000000000000975","article-title":"Letter to the Editor: the WHO HDV RNA international standard does not reflect variability of real-world samples","volume":"81","author":"Sandmann","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.jcv.2026.105971_bib14","unstructured":"Altona diagnostics. Instructions for use - altostar HDV RT-PCR kit 1.5. \u3008https:\/\/altona-diagnostics.com\/wp-content\/uploads\/2025\/10\/AS-HDV-1.5_MAN\u3009- AS0401540-EN-S02_WEB.pdf. Accessed 14 May, 2026."},{"key":"10.1016\/j.jcv.2026.105971_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2021.104932","article-title":"Reliable quantification of plasma HDV RNA is of paramount importance for treatment monitoring: a european multicenter study","volume":"142","author":"Stelzl","year":"2021","journal-title":"J. Clin. Virol."},{"issue":"5","key":"10.1016\/j.jcv.2026.105971_bib16","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1128\/JCM.43.5.2363-2369.2005","article-title":"Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients","volume":"43","author":"Le Gal","year":"2005","journal-title":"J. Clin. Microbiol."},{"issue":"5","key":"10.1016\/j.jcv.2026.105971_bib17","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1128\/JCM.03521-13","article-title":"Serological and molecular diagnosis of hepatitis delta virus infection: Results of a french national quality control study","volume":"52","author":"Brichler","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jcv.2026.105971_bib18","doi-asserted-by":"crossref","unstructured":"Anolli M.P., Renteria S.U., Degasperi E., et al. Quantification of plasma HDV RNA in untreated and bulevirtide-treated patients with CHD: A comparison between robogene 2.0, eurobioplex and altostar. Poster presented at EASL congress 2024, Milan, Italy. 2024.","DOI":"10.1016\/j.dld.2024.01.050"},{"issue":"2","key":"10.1016\/j.jcv.2026.105971_bib19","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3851\/IMP3281","article-title":"Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation","volume":"24","author":"Bremer","year":"2019","journal-title":"Antivir. Ther."},{"issue":"3","key":"10.1016\/j.jcv.2026.105971_bib20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/liv.15795","article-title":"Quantification of serum HDV RNA by robogene 2.0 in HDV patients is significantly influenced by the extraction methods","volume":"44","author":"Anolli","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.jcv.2026.105971_bib21","unstructured":"Roboscreen diagnostics. Instructions for use - RoboGene HDV RNA quantification kit 2.0.\u3008https:\/\/www.roboscreen.com\/index.php?eID=dumpFile&t=f&f=98&token=b95dff60bc2\u3009 5c68f7e34196bfa2d2a3278dbd26d. Accessed 14 May, 2026."},{"issue":"6","key":"10.1016\/j.jcv.2026.105971_bib22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/hep.29574","article-title":"Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains","volume":"66","author":"Le Gal","year":"2017","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jcv.2026.105971_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cgh.2013.01.025","article-title":"Commercial real-time reverse transcriptase PCR assays can underestimate or fail to quantify hepatitis delta virus viremia","volume":"11","author":"Brichler","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jcv.2026.105971_bib24","unstructured":"Product information RoboGene HDV RNA quantification kit 2.0 \u3008https:\/\/www.roboscreen.com\/products\/viral-pathogens\/robogene-hdv-rna\u3009- quantification-kit-20\/. Accessed 23 March, 2026."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653226000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:17:46Z","timestamp":1785878266000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653226000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":24,"alternative-id":["S1386653226000600"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105971","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2026.105971","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105971"}}